{"id":52588,"date":"2024-08-05T12:47:08","date_gmt":"2024-08-05T12:47:08","guid":{"rendered":"https:\/?p=52588"},"modified":"2024-08-05T12:47:08","modified_gmt":"2024-08-05T12:47:08","slug":"biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/","title":{"rendered":"BioNTech&#8217;s Q2 Revenues Plummet Amid Declining COVID-19 Vaccine Demand"},"content":{"rendered":"<p><span style=\"font-weight: 400;\"><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/BNTX\">BioNTech (BNTX)<\/a>, a prominent player in the biotechnology sector, has announced its financial results for the second quarter of 2024, showcasing a mix of significant achievements and challenges. This quarter has been pivotal for BioNTech as it continues to navigate the evolving landscape of the biotechnology industry.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Key Insights from BioNTech&#8217;s Q2 Reports:\u00a0<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Below are the key findings from BioNTech\u2019s Q2 earnings.\u00a0<\/span><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\"><strong>Revenue Decline:<\/strong> In Q2 2024, BioNTech reported revenues of \u20ac128.7 million, down from \u20ac167.7 million in the same period of the previous year. This decrease is mainly due to the reduced demand for COVID-19 vaccines as the market shifts from pandemic urgency to seasonal endemic management.<\/span><\/li>\n<li><span style=\"font-weight: 400;\"><strong>Revenue Guidance Maintained:<\/strong> Despite the revenue decline, BioNTech has reiterated its guidance for total revenues for the full year, expecting to be in the range of \u20ac2.5 to \u20ac3.1 billion.<\/span><\/li>\n<li><span style=\"font-weight: 400;\"><strong>R&amp;D Expenditures:<\/strong> BioNTech allocated \u20ac584.6 million towards research and development (R&amp;D) in Q2 2024. This investment is primarily focused on oncology and mRNA technology, underlining BioNTech&#8217;s commitment to diversifying its portfolio and advancing its oncology pipeline.<\/span><\/li>\n<li><span style=\"font-weight: 400;\"><strong>Net Loss:<\/strong> The company reported a significant net loss of \u20ac807.8 million for Q2 2024, a sharp increase from the \u20ac190.4 million loss in the same quarter of the previous year. The increased net loss is mainly due to substantial R&amp;D investments and costs associated with scaling up clinical trials and commercial activities.<\/span><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/\"><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter wp-image-52590 size-full\" src=\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2024\/08\/sta-stock-chart-widget-84.png\" alt=\"BNTX stock chart widget \" width=\"522\" height=\"658\" srcset=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/08\/sta-stock-chart-widget-84.png 522w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/08\/sta-stock-chart-widget-84-238x300.png 238w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/08\/sta-stock-chart-widget-84-119x150.png 119w\" sizes=\"(max-width: 522px) 85vw, 522px\" \/><\/a><\/p>\n<h2><strong>Management Discussion and Analysis:\u00a0<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Professor Ugur Sahin, CEO and Co-Founder of BioNTech, emphasized the importance of the advancements in their oncology portfolio, which includes individualized and off-the-shelf mRNA vaccine platforms. Noteworthy progress was made in clinical trials for cancer vaccine candidates such as BNT111 and the initiation of trials for novel drug combinations aimed at enhancing anti-tumor activity.<\/span><\/p>\n<p><!-- STA Widget BEGIN --><\/p>\n<div>\n<div class=\"sta-symbol-analyst-ratings-widget-display\">\n<p><a style=\"text-decoration: none; color: #4b6db5 !important;\" href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/BNTX\" target=\"_blank\" rel=\"noopener\">BNTX Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n<p><script class=\"symbol-analyst-ratings\" type=\"text\/javascript\" src=\"https:\/\/www.stocktargetadvisor.com\/assets\/js\/symbol_analyst_ratings.js\" data-symbol=\"BNTX\" data-theme=\"wt_bg_trans\" data-uid=\"22975908166b0c82130e9766b0c82130e98\" data-width=\"500\" >\n\t\t<\/script><\/p>\n<\/div>\n<h2><strong>Stock Target Advisor&#8217;s Analysis on BioNTech:\u00a0<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\"><a href=\"https:\/\/www.stocktargetadvisor.com\/\">Stock Target Advisor<\/a> analysis of BioNTech SE is bullish, supported by three positive signals and one negative signal. The average analyst target price for BioNTech SE over the next 12 months is USD 111.43, with a consensus rating of &#8220;Buy.&#8221; Despite the recent stock price at USD 82.01, analysts remain optimistic about BioNTech\u2019s future performance, projecting a potential price increase.<\/span><\/p>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/pricing\"><img decoding=\"async\" class=\"alignnone wp-image-45638 size-full\" src=\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2024\/01\/STAs-Banner-Image.png\" alt=\"STA's banner Image\" width=\"1200\" height=\"350\" srcset=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/01\/STAs-Banner-Image.png 1200w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/01\/STAs-Banner-Image-300x88.png 300w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/01\/STAs-Banner-Image-1024x299.png 1024w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/01\/STAs-Banner-Image-150x44.png 150w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/01\/STAs-Banner-Image-768x224.png 768w\" sizes=\"(max-width: 709px) 85vw, (max-width: 909px) 67vw, (max-width: 1362px) 62vw, 840px\" \/><\/a><\/p>\n<h2><strong>Conclusion:\u00a0<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">BioNTech&#8217;s second quarter of 2024 reflects both the opportunities and challenges faced by the company. The substantial investments in R&amp;D and strategic advancements in their oncology portfolio signify BioNTech&#8217;s commitment to long-term growth and diversification beyond COVID-19 vaccines.<\/span><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BioNTech (BNTX), a prominent player in the biotechnology sector, has announced its financial results for the second quarter of 2024, showcasing a mix of significant&#8230;<\/p>\n","protected":false},"author":17,"featured_media":52591,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-52588","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BioNTech&#039;s Q2 Revenues Plummet Amid Declining COVID-19 Vaccine Demand | Stock Target Advisor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioNTech&#039;s Q2 Revenues Plummet Amid Declining COVID-19 Vaccine Demand\" \/>\n<meta property=\"og:description\" content=\"BioNTech (BNTX), a prominent player in the biotechnology sector, has announced its financial results for the second quarter of 2024, showcasing a mix of significant...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-05T12:47:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/08\/STAs-Blog-Images-2024-08-05T174504.469.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Muzzammil Ahmad\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/Muzzammil625\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Muzzammil Ahmad\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/\"},\"author\":{\"name\":\"Muzzammil Ahmad\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\"},\"headline\":\"BioNTech&#8217;s Q2 Revenues Plummet Amid Declining COVID-19 Vaccine Demand\",\"datePublished\":\"2024-08-05T12:47:08+00:00\",\"dateModified\":\"2024-08-05T12:47:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/\"},\"wordCount\":402,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/\",\"name\":\"BioNTech's Q2 Revenues Plummet Amid Declining COVID-19 Vaccine Demand | Stock Target Advisor\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2024-08-05T12:47:08+00:00\",\"dateModified\":\"2024-08-05T12:47:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioNTech&#8217;s Q2 Revenues Plummet Amid Declining COVID-19 Vaccine Demand\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\",\"name\":\"Muzzammil Ahmad\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"caption\":\"Muzzammil Ahmad\"},\"description\":\"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/\",\"https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625\"],\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BioNTech's Q2 Revenues Plummet Amid Declining COVID-19 Vaccine Demand | Stock Target Advisor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/","og_locale":"en_US","og_type":"article","og_title":"BioNTech's Q2 Revenues Plummet Amid Declining COVID-19 Vaccine Demand","og_description":"BioNTech (BNTX), a prominent player in the biotechnology sector, has announced its financial results for the second quarter of 2024, showcasing a mix of significant...","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2024-08-05T12:47:08+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/08\/STAs-Blog-Images-2024-08-05T174504.469.jpg","type":"image\/jpeg"}],"author":"Muzzammil Ahmad","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/Muzzammil625","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"Muzzammil Ahmad","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/"},"author":{"name":"Muzzammil Ahmad","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8"},"headline":"BioNTech&#8217;s Q2 Revenues Plummet Amid Declining COVID-19 Vaccine Demand","datePublished":"2024-08-05T12:47:08+00:00","dateModified":"2024-08-05T12:47:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/"},"wordCount":402,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/","name":"BioNTech's Q2 Revenues Plummet Amid Declining COVID-19 Vaccine Demand | Stock Target Advisor","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2024-08-05T12:47:08+00:00","dateModified":"2024-08-05T12:47:08+00:00","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/biontechs-q2-revenues-plummet-amid-declining-covid-19-vaccine-demand\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"BioNTech&#8217;s Q2 Revenues Plummet Amid Declining COVID-19 Vaccine Demand"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8","name":"Muzzammil Ahmad","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","caption":"Muzzammil Ahmad"},"description":"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.","sameAs":["https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/","https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625"],"url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/52588","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=52588"}],"version-history":[{"count":1,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/52588\/revisions"}],"predecessor-version":[{"id":52592,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/52588\/revisions\/52592"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/52591"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=52588"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=52588"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=52588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}